Vimarsana
Biggest News Aggregation in the World

Page 4 - Target Validation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Target Validation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Target Validation Today - Breaking & Trending Today

Drug Discovery Outsourcing Market to Reach USD 7.4 Billion, Globally, by 2031 at 7.5% CAGR: Allied Market Research - Vimarsana News

Drug Discovery Outsourcing Market to Reach USD 7.4 Billion, Globally, by 2031 at 7.5% CAGR: Allied Market Research

/PRNewswire/ -- Allied Market Research published a report, titled, "Drug Discovery Outsourcing Market by Workflow (Target Identification and Screening, Target...

Leveraging Clinical Trial Ready IHC Assays from Target Validation to Prospective Enrollment and CDx Development, Upcoming Webinar Hosted by Xtalks - Vimarsana News

Leveraging Clinical Trial Ready IHC Assays from Target Validation to Prospective Enrollment and CDx Development, Upcoming Webinar Hosted by Xtalks

Toronto, ON (PRWEB) October 11, 2022 -- Many clinical trials fail due to inadequately distinguishing between disease phenotypes and underlying drivers of

Source: prweb.com
Xtalks Announces its Life Science Webinar Calendar for October 2022 - Vimarsana News

Xtalks Announces its Life Science Webinar Calendar for October 2022

Toronto, ON (PRWEB) October 03, 2022 -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical

Source: prweb.com
Frontiers | Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021 - Vimarsana News

Frontiers | Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021

Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi that endangers almost 70 million people worldwide. The only two drugs that are currently approved for its treatment, benznidazole and nifurtimox, have controversial efficacy in adults and restricting safety issues, leaving thousands of patients without a suitable treatment. The neglect of Chagas disease is further illustrated by the lack of a robust and diverse drug discovery and development portfolio of new chemical entities, and it is of paramount importance to build a strong research and develo...

New substance suppresses the growth of harmful bacteria that cause periodontitis - Vimarsana News

New substance suppresses the growth of harmful bacteria that cause periodontitis

New substance suppresses the growth of harmful bacteria that cause periodontitis Targeted, efficient and with few side effects: A new method for combating periodontitis could render the use of broad-spectrum antibiotics superfluous. It was developed and tested for the first time by a team from Martin Luther University Halle-Wittenberg (MLU), the Fraunhofer Institute for Cell Therapy and Immunology IZI and Periotrap Pharmaceuticals GmbH. The aim is to neutralize only bacteria that cause periodontitis while sparing harmless bacteria. The study appeared in the Journal of Biological Chemistry. P...